N,N-二甲基-4-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)-1H-吡唑-1-丙胺 | 847818-72-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 硼酸衍生物
• 中文名称: N,N-二甲基-4-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)-1H-吡唑-1-丙胺
• 中文别名: 二甲基({3-[4-(四甲基-1,3,2-二氧杂硼硼烷-2-基)-1H-吡唑-1-基]丙基})胺
• 英文名称: N,N-dimethyl-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]propan-1-amine
• 英文别名: dimethyl-{3-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyrazol-1-yl]propyl}-amine；dimethyl-{3-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyrazol-1-yl]-propyl}-amine；N,N-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-propanamine；N,N-dimethyl-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]propan-1-amine
• CAS: 847818-72-8
• 化学式: C₁₄H₂₆BN₃O₂
• mdl: MFCD11983295
• 分子量: 279.19
• InChiKey: BNCRCOZKRXVUBY-UHFFFAOYSA-N

物化性质

• 沸点：
  76-78 °C(Press: 0.01 Torr)
• 密度：
  1.03±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.13
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  39.5
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-(6-bromo-2,3-dihydrobenzo[b][1,4]oxazin-4-yl)-6,7-dihydro-6,6-dimethylthiazolo[5,4-c]pyridin-4(5H)-one 、 N,N-二甲基-4-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)-1H-吡唑-1-丙胺 在 potassium phosphate 、 四(三苯基膦)钯 、 四丁基溴化铵 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 1.0h， 生成 2-(6-{1-[3-(dimethylamino)propyl]-1H-pyrazol-4-yl}-2,3-dihydro-4H-1,4-benzoxazin-4-yl)-6,6-dimethyl-6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one
  参考文献：
  名称：

  Optimization of a series of multi-isoform PI3 kinase inhibitors

  摘要：

  Optimization of the cellular and pharmacological activity of a novel series of PI3 kinase inhibitors targeting multiple isoforms is described. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.08.042
• 作为产物：
  描述：

  N,N-二甲氨基氯丙烷盐酸盐 在 氢氧化钾 、 正丁基锂 、 4 A molecular sieve 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 为溶剂， 反应 6.0h， 生成 N,N-二甲基-4-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)-1H-吡唑-1-丙胺
  参考文献：
  名称：

  1-烷基-1 H-吡唑-5-基和1烷基-1 H-吡唑-4-基硼酸频哪醇酯的合成

  摘要：

  从1 H-吡唑开始，合成并表征了多种1-烷基-1 H-吡唑-4-基和1-烷基-1 H-吡唑-5-基硼酸及其频哪醇酯。所述方法中的关键步骤是吡唑环的区域选择性锂化。合成的松果酸酯在长期保存下是稳定的，可以用作有机合成中的方便试剂。

  DOI：

  10.1002/jhet.5570410612

文献信息

• [EN] HETARYL-[1,8]NAPHTHYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS D'HÉTARYL-[1,8]NAPHTYRIDINE
  申请人：MERCK PATENT GMBH

  公开号：WO2011095196A1

  公开（公告）日：2011-08-11

  Novel hetaryl-[1,8]naphthyridine derivatives of formula (I) wherein R1, R2, W1, W3, W5 and W6 have the meaning according to claim 1, are inhibitors of ATP consuming proteins, and can be employed, inter alia, for the treatment of tumors.

  新型杂环-[1,8]萘啶衍生物的化学式（I），其中R1、R2、W1、W3、W5和W6的含义如权利要求书中所述，是ATP消耗蛋白的抑制剂，可用于治疗肿瘤。
• Hetaryl-[1,8]naphthyridine derivatives
  申请人：Jonczyk Alfred

  公开号：US20120295902A1

  公开（公告）日：2012-11-22

  Novel hetaryl-[1,8]naphthyridine derivatives of formula (I) wherein R1, R2, W 1 , W 3 , W 5 and W 6 have the meaning according to claim 1 , are inhibitors of ATP consuming proteins, and can be employed, inter alia, for the treatment of tumors.

  新型杂芳基-[1,8]萘啶衍生物的化学式（I），其中R1、R2、W1、W3、W5和W6的含义如权利要求书中所述，是ATP消耗蛋白的抑制剂，可用于治疗肿瘤。
• Discovery of a 5<i>H</i>-Benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-one (MK-2461) Inhibitor of c-Met Kinase for the Treatment of Cancer
  作者：Jason D. Katz、James P. Jewell、David J. Guerin、Jongwon Lim、Christopher J. Dinsmore、Sujal V. Deshmukh、Bo-Sheng Pan、C. Gary Marshall、Wei Lu、Michael D. Altman、William K. Dahlberg、Lenora Davis、Danielle Falcone、Ana E. Gabarda、Gaozhen Hang、Harold Hatch、Rachael Holmes、Kaiko Kunii、Kevin J. Lumb、Bart Lutterbach、Robert Mathvink、Naim Nazef、Sangita B. Patel、Xianlu Qu、John F. Reilly、Keith W. Rickert、Craig Rosenstein、Stephen M. Soisson、Kerrie B. Spencer、Alexander A. Szewczak、Deborah Walker、Wenxian Wang、Jonathan Young、Qinwen Zeng

  DOI：10.1021/jm200112k

  日期：2011.6.23

  c-Met is a transmembrane tyrosine kinase that mediates activation of several signaling pathways implicated in aggressive cancer phenotypes. In recent years, research into this area has highlighted c-Met as an attractive cancer drug target, triggering a number of approaches to disrupt aberrant c-Met signaling. Screening efforts identified a unique class of 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one kinase inhibitors, exemplified by 1. Subsequent SAR studies led to the development of 81 (MK-2461), a potent inhibitor of c-Met that was efficacious in preclinical animal models of tumor suppression. In addition, biochemical studies and X-ray analysis have revealed that this unique class of kinase inhibitors binds preferentially to the activated (phosphorylated) form of the kinase. This report details the development of 81 and provides a description of its unique biochemical properties.
• Synthesis of pinacol esters of 1-alkyl-1<i>H</i>-pyrazol-5-yl- and 1-alkyl-1<i>H</i>-pyrazol-4-ylboronic acids
  作者：Alexandre V. Ivachtchenko、Dmitry V. Kravchenko、Valentina I. Zheludeva、Dmitry G. Pershin

  DOI：10.1002/jhet.5570410612

  日期：2004.11

  1-alkyl-1H-pyrazol-4-yl and 1-alkyl-1H-pyrazol-5-ylboronic acids and their pinacol esters were synthesized and characterized. The key step in the described methodology is the regioselective lithiation of the pyrazole ring. The synthesized pinacolates are stable under prolonged storage and can be used as convenient reagents in organic synthesis.

  从1 H-吡唑开始，合成并表征了多种1-烷基-1 H-吡唑-4-基和1-烷基-1 H-吡唑-5-基硼酸及其频哪醇酯。所述方法中的关键步骤是吡唑环的区域选择性锂化。合成的松果酸酯在长期保存下是稳定的，可以用作有机合成中的方便试剂。
• Optimization of a series of multi-isoform PI3 kinase inhibitors
  作者：Benjamin Perry、Rebekah Beevers、Gavin Bennett、George Buckley、Tom Crabbe、Lewis Gowers、Lynwen James、Kerry Jenkins、Chris Lock、Verity Sabin、Sara Wright

  DOI：10.1016/j.bmcl.2008.08.042

  日期：2008.10

  Optimization of the cellular and pharmacological activity of a novel series of PI3 kinase inhibitors targeting multiple isoforms is described. (c) 2008 Elsevier Ltd. All rights reserved.